Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004041 · ClinicalTrials.gov registry record · Phase 1

Gene Therapy in Treating Patients With Recurrent Malignant Gliomas

A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Completed
Registry status
Phase 1
Development phase
8
Study locations

NCT00004041 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004041, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

COMPLETED
Registry status
Phase 1
Development phase
8
Study locations

Study Summary

RATIONALE: Inserting the gene for adenovirus p53 into a person's tumor may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have recurrent malignant gliomas.

Interventions

  • PROCEDURE conventional surgery
  • BIOLOGICAL Ad5CMV-p53 gene

Study Locations (8)

Texas

  • Simmons Cancer Center - Dallas - Dallas
  • University of Texas - MD Anderson Cancer Center - Houston
  • University of Texas Health Science Center at San Antonio - San Antonio

California

  • UCSF Cancer Center and Cancer Research Institute - San Francisco

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor

Pennsylvania

  • University of Pittsburgh Cancer Institute - Pittsburgh

Wisconsin

  • University of Wisconsin Comprehensive Cancer Center - Madison

Trial Details

FieldValue
Start Date 1999-02-25
Est. Completion 2003-07-01
Phase Phase 1

What the Registry Record Tells You About NCT00004041

The ClinicalTrials.gov registry entry for NCT00004041 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which conventional surgery is the first listed.

NCT00004041 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Texas, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00004041 about?

NCT00004041 is a clinical study titled "Gene Therapy in Treating Patients With Recurrent Malignant Gliomas". RATIONALE: Inserting the gene for adenovirus p53 into a person's tumor may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have recurrent malignant gliomas.

What is the current status of trial NCT00004041?

This trial is currently completed. It is a Phase 1 study. The study started on 1999-02-25. Estimated completion is 2003-07-01.

What conditions does trial NCT00004041 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00004041?

The interventions under investigation include: conventional surgery (PROCEDURE), Ad5CMV-p53 gene (BIOLOGICAL).

Who is sponsoring clinical trial NCT00004041?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004041 being conducted?

This trial has 8 study locations across California, Massachusetts, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.